Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.631
+0.001 (0.19%)
At close: Mar 9, 2026, 4:00 PM EDT
0.634
+0.003 (0.46%)
After-hours: Mar 9, 2026, 7:43 PM EDT

Kairos Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
3.831.931.630.481.761.03
Research & Development
1.770.410.080.090.180.02
Operating Expenses
5.62.341.710.571.941.05
Operating Income
-5.6-2.34-1.71-0.57-1.94-1.05
Interest Expense
--0.19-0.1-0.46-0.16-0.01
Other Non Operating Income (Expenses)
-0.13-0.67--0.02-0.04-
EBT Excluding Unusual Items
-5.66-3.2-1.81-1.05-2.15-1.05
Other Unusual Items
0.60.6----
Pretax Income
-5.06-2.6-1.81-1.05-2.15-1.05
Net Income
-5.06-2.6-1.81-1.05-2.15-1.05
Net Income to Common
-5.06-2.6-1.81-1.05-2.15-1.05
Shares Outstanding (Basic)
1711101099
Shares Outstanding (Diluted)
1711101099
Shares Change (YoY)
55.64%9.38%1.42%11.86%-3.12%-
EPS (Basic)
-0.31-0.23-0.17-0.10-0.23-0.11
EPS (Diluted)
-0.31-0.23-0.17-0.10-0.23-0.11
EBITDA
-5.44-2.18-1.55-0.41-1.85-
D&A For EBITDA
0.160.160.160.160.1-
EBIT
-5.6-2.34-1.71-0.57-1.94-1.05
Source: S&P Capital IQ. Standard template. Financial Sources.